Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

 
• By Emily Hayes

Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.

3d render illustration of human digestive system - front view

More from Immuno-oncology

More from Anticancer